Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis

Abstract Aims Long‐term treatment effect studies in large female Fabry patient groups are challenging to design because of phenotype heterogeneity and lack of appropriate comparison groups, and have not been reported. We compared long‐term cardiomyopathy and kidney function outcomes after agalsidase...

Full description

Saved in:
Bibliographic Details
Main Authors: Christoph Wanner, Ulla Feldt‐Rasmussen, Ana Jovanovic, Aleš Linhart, Meng Yang, Elvira Ponce, Eva Brand, Dominique P. Germain, Derralynn A. Hughes, John L. Jefferies, Ana Maria Martins, Albina Nowak, Bojan Vujkovac, Frank Weidemann, Michael L. West, Alberto Ortiz
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:ESC Heart Failure
Subjects:
Agalsidase beta
Enzyme replacement therapy
Fabry disease
Cardiomyopathy
Kidney function
Female patients
Online Access:https://doi.org/10.1002/ehf2.12647
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/ehf2.12647

Similar Items